GlassScriptPhysician profile
Richard A Paat
NPI 1316947021
$554.05
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $166 · 2022: $20.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $108.02 | 2019-2020 | |
| Amgen INC. | $106.29 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.92 | 2019 | |
| Pfizer INC. | $53.72 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.22 | 2019-2020 | |
| Novo Nordisk INC | $32.64 | 2019 | |
| Allergan, INC. | $25.95 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $23.34 | 2019 | |
| Abbvie INC. | $20.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.56 | 2020 | |
| Lilly USA, LLC | $11.47 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Paat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.